Company: BLLN
Filing Date: 2025-06-20
Form Type: DRS
Source: 0000950123-25-006095
Chunk: 126

Company: BillionToOne, Inc.
Filing Date: 2025-06-20
Form: DRS
Chunk 126
---
 (equivalent cost of identifying one affected pregnancy vs. sequential carrier screening). In comparison, the CLFS price for our sgNIPT was established at $879.47. We often use the calculation of health savings in our discussions with the payors to gain in-networkstatus. 93

While our ASPs have significantly increased over time, they are, in aggregate, still less than ~50% of the CLFS rates for our tests. This is primarily because (i) we are not in-networkwith all payors, (ii) when we get in-networkwith a payor, we may agree to a rate that is less than 100% of the CLFS in return for more consistent in-networkpayments for our services, and (iii) not all of our tests are considered covered benefits by all payors. As we increase contracting and coverage of our tests, we believe that ASPs can continue to increase over time. Historically, our market access and reimbursement teams have pursued strategies to increasing our ASPs by expanding our payor coverage and reimbursement. We believe these strategies will continue to grow our ASPs over time. Examples include:

| • |     | Securing unique reimbursement and procedural codes: A critical aspect of our market access strategy is to                                                                                                                                           
 obtain specific reimbursement and procedural codes for our tests, rather than using the generic codes that may not fully capture the uniqueness and value that our tests provide. These codes facilitate appropriate billing and reimbursement from 
 payors and drive broader clinical adoption. For instance, our UNITY Carrier Screen was assigned a PLA code, 0449U, which has received CMS pricing of $1,825, effective January 1, 2025. Similarly, our Northstar Select and Northstar Response      
 products received PLA codes 0487U and 0486U, respectively, with CMS pricing of $2,920 and $1,644 respectively. As our codes of 0449U and 0487U have been added to the coverage policies of payors, including Medicare for the latter, our ASPs have 
 increased.                                                                                                                                                                                                                                          |

| • |     | Expanding payor coverage criteria and clinical utility: Changes in payor policies, such as the expansion of                                                                                                                                              
 coverage criteria or the recognition of new indications, can have a pronounced effect on our revenues and ASPs. In 2024, several payors began covering additional tests within our prenatal panel, specifically those for 22q11.2 deletion syndrome (22q 
 microdeletion), Rh